StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Sarepta Therapeutics (SRPT): R&D Day Should Reveal Gene Therapy Data - Baird
May 4, 2018 6:43 AM
Baird analyst, Brian Skorney, reiterated his Outperform rating on shares of Sarepta Therapeutics (NASDAQ: SRPT) after the company reported $64.6M ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst EPS Change
Analyst EPS View
Next Articles
Sarepta Therapeutics (SRPT) PT Raised to $96 at H.C. Wainwright
May 7, 2018 8:17 AM
Sarepta Therapeutics (SRPT) PT Raised to $109 at Needham & Company
May 7, 2018 6:20 AM
Sarepta Therapeutics (SRPT) PT Raised to $98 at RBC Capital
May 4, 2018 8:50 AM
Sarepta Therapeutics (SRPT) PT Lowered to $90 at H.C. Wainwright
May 4, 2018 7:14 AM
